ICAN investigators were, in alphabetical order of last name: L. Eugene Arnold, M.D. (OSU), Martijn Arns, Ph.D. (Research Institute Brainclinics & Utrecht University), Justin Barterian, Ph.D. (OSU), Sudeshna Dasgupta, M.D. (UNCA), Roger deBeus, Ph.D. (UNCA), Laurence Hirshberg, Ph.D. (Brown University), Jill A. Hollway, Ph.D., M.A. (OSU), Cynthia Kerson, Ph.D. (Saybrook University, APEd), Helena Kraemer, Ph.D. (Stanford University), Joel Lubar, Ph.D. (University of Tennessee), Keith McBurnett, Ph.D. (UCSF), Vincent Monastra, Ph.D. (FPI Attention Disorders Clinic), Robert Rice, Jr., Ph.D. (OSU), Xueliang Pan, Ph.D. (OSU), and Craig Williams, M.D. (OSU). Post-docs were: Sarah Black, Ph.D. (OSU), Michelle Roley-Roberts, Ph.D. (OSU), and Quyen Wells, Ph.D. (OSU). Coordinators, trainers, and other staff contributing essentially to the study were, in alphabetical order: Rachel Bergman, BA (OSU), Shea Connor, BA (UNCA), Teryl Higgins, M.A. (UNCA), Noelle McConnell, BS (UNCA), Mae Nicopolis, BA (UNCA), Kristin Page, BS (OSU), Yubo Tan, M.A. (OSU), Rachel Rhodes, MLAS (UNCA), Constance Schrader, M.A. (UNCA).
Funding Information:
Some of the data for this report came from the International Collaborative ADHD Neurofeedback (ICAN) study, a two-site randomized controlled trial funded by NIMH Grant R01 MH 100144 to Ohio State University (OSU; L. Eugene Arnold, M.D., PI) with subaward to University of North Carolina at Asheville (UNCA; Roger deBeus, Ph.D., PI) and by the Center for Clinical and Translational Science at The Ohio State University (ARRA Pilot Project UL1 RR025755 project 60023888). The iSPOT-A study was funded entirely by Brain Resource (BRC). Acknowledgements
Funding Information:
Dr. Roger deBeus has received research funding from the Commonwealth Health Research Board of Virginia, Riverside Healthcare Foundation, VuBay Foundation, Edwin Joseph Foundation, and NIMH. Dr. Cynthia Kerson is President of Applied Psychophysiology Education (APEd). Dr. Vince Monastra has received royalty payments from the Biofeedback Federation of Europe for the development of the Monastra-Lubar ADHD Assessment Suite. Dr. L. Eugene Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks), has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire. Martijn Arns is unpaid research director of the Brainclinics Foundation, a minority shareholder in neuroCare Group (Munich, Germany), and a co-inventor on 4 patent applications (A61B5/0402; US2007/0299323, A1; WO2010/139361 A1; WO2017/099603 A1) related to EEG, neuromodulation and psychophysiology, but does not own these or receives any proceeds related to these patents; Research Institute Brainclinics received research funding from Brain Resource (Sydney, Australia), UrgoTech and neuroCare Group (Munich, Germany), and equipment support from Deymed, neuroConn and Magventure unrelated to this manuscript. Hanneke van Dijk, Michelle Roley-Roberts and Xueliang Pan declare that they have no conflict of interest.